Reports
Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global telmisartan market attained a value of about USD 3,574 million in 2020. The market is further expected to grow at a CAGR of 3.5% during the forecast period of 2023-2028 to reach approximately USD 4,393 million by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global market for telmisartan is being driven by the prevalence and rise in diseases like hypertension and other cardiac diseases. The advent of the coronavirus forced governments across the world to implement stringent lockdown rules, owing to which many companies were impelled to cut down salaries and jobs. As a result of elongated periods of unemployment and other pandemic-induced stress, there has been a substantial rise in cardiac diseases. Telmisartan works against high blood pressure by being effective in gene modification for insulin sensitisation and regulating glucose and lipid metabolism. Furthermore, in addition to stress, other factors such as spur in the geriatric population and unhealthy lifestyle are also giving rise to diseases like chronic diabetes and other diseases, which augment the market growth for telmisartan. The drug is used to lower the risk of heart attacks and kidney failures in patients with diabetes, hence invigorating the industry growth.
Telmisartan refers to a non-peptide angiotensin receptor blocker/ ARB, popularly used as a prescription drug for treating cardiovascular disorders. The drug functions to relax the blood vessels and promote the healthy functioning of the kidneys.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market, based on strength, can be segmented into:
Based on condition, the market can be divided into:
On the basis of distribution channels, the market is classified into:
The EMR report looks into the regional markets of telmisartan like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The robust growth of the pharmaceutical sector is supplementing the market growth of telmisartan to treat chronic diseases like those related to the cardiovascular system. Significant contributions towards research and development (R&D) projects to explore the various benefits of telmisartan in the treatment of diabetic nephropathy and other kidney disorders are generating growth opportunities for the industry growth. In addition, pharmaceutical manufacturers are working towards the development of generic versions of telmisartan medications to provide cost-effective treatment to patients suffering from hypertension and other cardiovascular diseases, consequently augmenting the market growth.
Furthermore, owing to the presence of prominent pharmaceutical players and well-funded research centres in North America, the region is estimated to dominate the market growth of telmisartan over the forecast period. The growth in the region can also be attributed to the prevalence of chronic diseases due to unhealthy lifestyles. Thus, such factors are contributing to the growth of the telmisartan industry.
The report presents a detailed analysis of the following key players in the global telmisartan market, looking into their capacity, market share, and latest developments like capacity expansions, plant turnabouts and mergers and acquisitions.
The comprehensive report looks at the micro and macro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of the Porter’s Five Forces Model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2018-2022 |
Forecast Period | 2023-2028 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Strength, Condition, Distribution Channel, Region |
Breakup by Strength | 20mg, 40mg, 80mg |
Breakup by Condition | Hypertension, Stroke, Cardiac Arrest, Others |
Breakup by Distribution Channel | Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online |
Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | Novartis AG, Astellas Pharma Inc., Nippon Boehringer Ingelheim, Abbott, Hema Pharmaceuticals Pvt. Ltd., Pfizer Inc., Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Telmisartan Market Analysis
8.1 Key Industry Highlights
8.2 Global Telmisartan Historical Market (2018-2022)
8.3 Global Telmisartan Market Forecast (2023-2028)
8.4 Global Telmisartan Market by Strength
8.4.1 20mg
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 40mg
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 80mg
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.5 Global Telmisartan Market by Condition
8.5.1 Hypertension
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Stroke
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Cardiac Arrest
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Others
8.6 Global Telmisartan Market by Distribution Channel
8.6.1 Hospital Pharmacies
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Retail Pharmacies and Drug Stores
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Online
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.7 Global Telmisartan Market by Region
8.7.1 North America
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.2 Europe
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.7.3 Asia Pacific
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2018-2022)
8.7.3.3 Forecast Trend (2023-2028)
8.7.4 Latin America
8.7.4.1 Market Share
8.7.4.2 Historical Trend (2018-2022)
8.7.4.3 Forecast Trend (2023-2028)
8.7.5 Middle East and Africa
8.7.5.1 Market Share
8.7.5.2 Historical Trend (2018-2022)
8.7.5.3 Forecast Trend (2023-2028)
9 North America Telmisartan Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2022)
9.1.3 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2022)
9.2.3 Forecast Trend (2023-2028)
10 Europe Telmisartan Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2022)
10.1.3 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2022)
10.2.3 Forecast Trend (2023-2028)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2022)
10.3.3 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2022)
10.4.3 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Telmisartan Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2022)
11.1.3 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2022)
11.2.3 Forecast Trend (2023-2028)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2022)
11.3.3 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2022)
11.4.3 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2022)
11.5.3 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Telmisartan Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2022)
12.1.3 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2022)
12.2.3 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2022)
12.3.3 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Telmisartan Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2022)
13.1.3 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2022)
13.2.3 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2022)
13.3.3 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2022)
13.4.3 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Novartis AG
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Astellas Pharma Inc.
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Nippon Boehringer Ingelheim
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Abbott
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Hema Pharmaceuticals Pvt. Ltd.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Pfizer Inc.
15.2.6.1 Company Overview
15.2.6.2 Product Portfolio
15.2.6.3 Demographic Reach and Achievements
15.2.6.4 Certifications
15.2.7 Others
16 Key Trends and Developments in the Market
Additional Customisations Available
1 Manufacturing Process
1.1 Overview
1.2 Detailed Process Flow
1.3 Operation Involved
List of Key Figures and Tables
1. Global Telmisartan Market: Key Industry Highlights, 2018 and 2028
2. Global Telmisartan Historical Market: Breakup by Strength (USD Million), 2018-2022
3. Global Telmisartan Market Forecast: Breakup by Strength (USD Million), 2023-2028
4. Global Telmisartan Historical Market: Breakup by Condition (USD Million), 2018-2022
5. Global Telmisartan Market Forecast: Breakup by Condition (USD Million), 2023-2028
6. Global Telmisartan Historical Market: Breakup by Distribution Channel (USD Million), 2018-2022
7. Global Telmisartan Market Forecast: Breakup by Distribution Channel (USD Million), 2023-2028
8. Global Telmisartan Historical Market: Breakup by Region (USD Million), 2018-2022
9. Global Telmisartan Market Forecast: Breakup by Region (USD Million), 2023-2028
10. North America Telmisartan Historical Market: Breakup by Country (USD Million), 2018-2022
11. North America Telmisartan Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Europe Telmisartan Historical Market: Breakup by Country (USD Million), 2018-2022
13. Europe Telmisartan Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Asia Pacific Telmisartan Historical Market: Breakup by Country (USD Million), 2018-2022
15. Asia Pacific Telmisartan Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Latin America Telmisartan Historical Market: Breakup by Country (USD Million), 2018-2022
17. Latin America Telmisartan Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Middle East and Africa Telmisartan Historical Market: Breakup by Country (USD Million), 2018-2022
19. Middle East and Africa Telmisartan Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Global Telmisartan Market Structure
The global telmisartan market attained a value of nearly USD 3,574 million in 2020.
The market is projected to grow at a CAGR of 3.5% in the forecast period of 2023-2028.
The market is estimated to witness healthy growth in the forecast period of 2023-2028 to reach about USD 4,393 million by 2026.
The telmisartan industry is being driven by the rise in prevalence of cardiovascular diseases like hypertension due to pandemic-induced stress, unhealthy lifestyle, and a rise in geriatric population.
Investments in the research and development (R&D) projects to explore the development of telmisartan in the treatment of diabetes is anticipated to propel the market growth.
The major regional markets for telmisartan are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
On the basis of strength, the market can be categorised into 20mg, 40mg, and 80mg.
Based on condition, the market can be segmented into hypertension, stroke, and cardiac arrest, among others.
The major distribution channels of telmisartan include hospital pharmacies, retail pharmacies and drug stores, and online channels.
The major players in the industry are Novartis AG, Astellas Pharma Inc., Nippon Boehringer Ingelheim, Abbott, Hema Pharmaceuticals Pvt. Ltd., and Pfizer Inc, among others.
The global telmisartan market attained a value of about USD 3,574 million in 2020, driven by the rising cases of hypertension and cardiovascular diseases. Aided by the robustly growing pharmaceutical sector, the market is expected to grow at a CAGR of 3.5% in the forecast period of 2023-2028 to reach nearly USD 4,393 million by 2026.
EMR’s meticulous research methodology delves deep into the market covering the macro and micro aspects of the industry. The market, on the basis of strength, can be divided into 20mg, 40mg, and 80mg. Based on condition, the market can be divided into hypertension, stroke, and cardiac arrest, among others. Based on distribution channels, the market can be classified into hospital pharmacies, retail pharmacies and drug stores, and online channels, among others. The major regional markets for telmisartan are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa. They key players in the industry are Novartis AG, Astellas Pharma Inc., Nippon Boehringer Ingelheim, Abbott, Hema Pharmaceuticals Pvt. Ltd., and Pfizer Inc, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.